The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.

Saved in:

Bibliographic Details
Title:	The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.
Authors:	Babu G; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Saldanha SC; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Kuntegowdanahalli Chinnagiriyappa L; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Jacob LA; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Mallekavu SB; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Dasappa L; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Kiran PR; Department of Community Health, St. John's Medical College, Bangalore 560034, India., Sreevatsa A; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Appachu S; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Unnikrishnan V; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India., Arroju V; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India.
Source:	Chemotherapy research and practice [Chemother Res Pract] 2016; Vol. 2016, pp. 3439707. Date of Electronic Publication: 2016 Jan 27.
Publication Type:	Journal Article
Journal Info:	Publisher: Hindawi Pub. Corp Country of Publication: Egypt NLM ID: 101566606 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2090-2107 (Print) Linking ISSN: 20902107 NLM ISO Abbreviation: Chemother Res Pract Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Be the first to leave a comment!